Stay updated on Nivolumab and Brentuximab Vedotin in Older Hodgkin Lymphoma Clinical Trial
Sign up to get notified when there's something new on the Nivolumab and Brentuximab Vedotin in Older Hodgkin Lymphoma Clinical Trial page.

Latest updates to the Nivolumab and Brentuximab Vedotin in Older Hodgkin Lymphoma Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedThe page presents details for a phase II trial of nivolumab and brentuximab vedotin in older or chemotherapy-ineligible patients with untreated Hodgkin lymphoma. It also includes participant criteria, study locations, outcome measures, and posted results.SummaryDifference59%

- Check18 days agoChange DetectedThe clinical trial record for nivolumab and brentuximab vedotin is no longer displayed; the page instead shows a 403 Forbidden message.SummaryDifference19%

- Check25 days agoChange DetectedA sitewide notice announces that NIH is using “Super Intelligence” in place of “Artificial Intelligence” during a transition. It appears above the study page, which displays a 403 error.SummaryDifference1%

- Check32 days agoChange DetectedThe ClinicalTrials.gov footer now shows revision v3.7.2 instead of v3.7.1.SummaryDifference0.2%

- Check39 days agoChange DetectedThe site revision label in the footer changes from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check60 days agoChange DetectedThe page now displays a 403 Forbidden error, replacing the study content with a 403 message and site chrome. This indicates the study record is not accessible at the moment.SummaryDifference19%

Stay in the know with updates to Nivolumab and Brentuximab Vedotin in Older Hodgkin Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab and Brentuximab Vedotin in Older Hodgkin Lymphoma Clinical Trial page.